−0.5ILS
−78.01 MILS
32.48 MILS
187.49 M
About LINEAGE THERAP
Sector
Industry
CEO
Brian M. Culley
Website
Headquarters
Carlsbad
Employees (FY)
75
Founded
1990
FIGI
BBG009YWLGV9
Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of LCTX is 433.3 ILA — it has decreased by 1.19% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on TASE exchange LINEAGE THERAP stocks are traded under the ticker LCTX.
LINEAGE THERAP is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
LCTX stock is 1.98% volatile and has beta coefficient of 0.50. Check out the list of the most volatile stocks — is LINEAGE THERAP there?
LCTX earnings for the last quarter are −0.15 ILA per share, whereas the estimation was −0.16 ILA resulting in a 4.00% surprise. The estimated earnings for the next quarter are −0.16 ILA per share. See more details about LINEAGE THERAP earnings.
LINEAGE THERAP revenue for the last quarter amounts to 4.76 M ILA despite the estimated figure of 9.93 M ILA. In the next quarter revenue is expected to reach 9.60 M ILA.
Yes, you can track LINEAGE THERAP financials in yearly and quarterly reports right on TradingView.
LCTX stock has fallen by 12.75% compared to the previous week, the month change is a 5.82% fall, over the last year LINEAGE THERAP has showed a 14.25% decrease.
LCTX net income for the last quarter is −17.34 M ILS, while the quarter before that showed −27.16 M ILS of net income which accounts for 36.17% change. Track more LINEAGE THERAP financial stats to get the full picture.
Today LINEAGE THERAP has the market capitalization of 809.59 M, it has decreased by 4.17% over the last week.
No, LCTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, LCTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade LINEAGE THERAP stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 23, 2024, the company has 75.00 employees. See our rating of the largest employees — is LINEAGE THERAP on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So LINEAGE THERAP technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating LINEAGE THERAP stock shows the sell signal. See more of LINEAGE THERAP technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on LINEAGE THERAP future price: according to them, LCTX price has a max estimate of 2577.03 ILA and a min estimate of 1472.59 ILA. Read a more detailed LINEAGE THERAP forecast: see what analysts think of LINEAGE THERAP and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. LINEAGE THERAP EBITDA is −87.29 M ILS, and current EBITDA margin is −268.76%. See more stats in LINEAGE THERAP financial statements.